Biocept, Inc. (BIOC) financial statements (2020 and earlier)

Company profile

Business Address 5810 NANCY RIDGE DR
SAN DIEGO, CA 92121
State of Incorp.
Fiscal Year End December 31
SIC 8071 - Medical Laboratories (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments732595
Cash and cash equivalents732595
Receivables321000
Inventory, net of allowances, customer advances and progress billings110100
Inventory110100
Deferred costs     1
Other undisclosed current assets00000(1)
Total current assets:11646106
Noncurrent Assets
Finance lease, right-of-use asset2
Operating lease, right-of-use asset1
Property, plant and equipment133211
Deferred costs     0
Other noncurrent assets     0
Other undisclosed noncurrent assets     (0)
Total noncurrent assets:433211
TOTAL ASSETS:15978117
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities443222
Accounts payable221111
Accrued liabilities222111
Employee-related liabilities     1
Interest and dividends payable     0
Debt212220
Derivative instruments and hedges, liabilities     0
Other undisclosed current liabilities0 000(1)
Total current liabilities:655431
Noncurrent Liabilities
Long-term debt and lease obligation1112310
Long-term debt, excluding current maturities   1310
Finance lease, liability1
Capital lease obligations11100
Liabilities, other than long-term debt 00001
Deferred revenue and credits0001
Deferred rent credit 0
Other undisclosed noncurrent liabilities   00(5)
Total noncurrent liabilities:111345
Total liabilities:766777
Stockholders' equity
Stockholders' equity attributable to parent83114(0)
Common stock000000
Additional paid in capital248223197174159138
Accumulated deficit(240)(220)(195)(174)(155)(138)
Total stockholders' equity:83114(0)
TOTAL LIABILITIES AND EQUITY:15978117

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues535310
Revenue, net17   
Other income   00
Cost of revenue(11)(10)(9)(7)(5)(2)
Gross profit:(6)(7)(4)(4)(4)(2)
Operating expenses(17)(17)(17)(14)(12)(12)
Other undisclosed operating income     0
Operating loss:(23)(24)(21)(18)(16)(14)
Nonoperating expense(2)(0)(0)(0)(1)(2)
Interest and debt expense(0)(0)(0)(1)(1)(2)
Loss from continuing operations before equity method investments, income taxes:(26)(25)(22)(19)(18)(18)
Other undisclosed income from continuing operations before income taxes000112
Loss from continuing operations before income taxes:(25)(25)(22)(18)(17)(16)
Income tax expense(0)(0)(0)(0)(0)(0)
Net loss attributable to parent:(25)(25)(22)(18)(17)(16)
Other undisclosed net loss available to common stockholders, basic(0)(1)    
Net loss available to common stockholders, diluted:(26)(25)(22)(18)(17)(16)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(25)(25)(22)(18)(17)(16)
Comprehensive loss, net of tax, attributable to parent:(25)(25)(22)(18)(17)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: